TopoTarget announces the European divestiture of Savene® to SpePharm Holding, BV and reconfirms the focus to develop and commercialise Belinostat
PALADIN AND SPEPHARM ANNOUNCE NEW STRATEGIC RELATIONSHIP
SpePharm announces the acquisition of Savene® from TopoTarget, an €11 million new round of financing, and a strategic partnership with Paladin Labs, Inc.
OCTOPLUS SUCCESSFULLY RAISES € 6 MILLION
Anteis announces new partnership with Sanofi-Aventis
Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
Prism Pharmaceuticals Receives FDA Approval of NEXTERONE ®
Indevus Pharmaceuticals Announces Definitive Merger